Midterm Exam: NR565/ NR 565 Advanced Pharmacology Care
of the Fundamentals Exam | Questions and Verified Answers
(2025/ 2026 Update)- Chamberlain
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Questions 1–30
Question 1
A nurse practitioner is calculating the time required for a drug to reach steady-state plasma
concentration in a patient. Which pharmacokinetic parameter is primarily used to determine
this timeframe?
A. Volume of distribution
B. Bioavailability
C. Elimination half-life
D. Clearance rate
Rationale: The elimination half-life determines the time to reach steady state. It takes
approximately 4–5 half-lives to achieve steady-state plasma concentration. Volume of
distribution affects loading dose calculations, while bioavailability affects the fraction of drug
reaching systemic circulation. Clearance determines the maintenance dose required.
Question 2
A patient is prescribed oral morphine for severe pain but reports it is much less effective than
the intravenous morphine received in the hospital. This difference in efficacy is primarily due to
which pharmacokinetic concept?
A. First-pass effect
B. Enterohepatic recirculation
C. Active tubular secretion
D. Zero-order elimination
Rationale: Oral morphine undergoes extensive hepatic metabolism before reaching
systemic circulation, significantly reducing its bioavailability compared to intravenous
administration. The first-pass effect describes metabolism of an orally administered drug by the
liver via the portal circulation before it reaches systemic circulation, reducing the fraction of
active drug available.
,Question 3
The therapeutic index of a drug is defined as:
A. The ratio of the minimum effective dose to the maximum tolerated dose
B. The ratio of the toxic dose to the effective dose for 50% of the population
C. The difference between peak and trough drug concentrations
D. The ratio of the drug's half-life to its dosing interval
Rationale: The therapeutic index is the ratio of TD₅₀ (toxic dose for 50% of population) to
ED₅₀ (effective dose for 50% of population). A narrow therapeutic index means there is a small
margin between therapeutic and toxic doses, requiring careful monitoring. Drugs with narrow
therapeutic indices include warfarin, digoxin, lithium, and phenytoin.
Question 4
A drug that binds to a receptor and produces a biological response is best described as a:
A. Antagonist
B. Partial agonist
C. Agonist
D. Allosteric modulator
Rationale: An agonist binds to a receptor and activates it, producing a biological response.
Antagonists bind to receptors but do not activate them (they block the receptor). Partial
agonists produce a submaximal response even when all receptors are occupied. Allosteric
modulators bind at a site different from the primary ligand binding site.
Question 5
A 65-year-old male with cirrhosis is prescribed a medication that undergoes extensive first-pass
hepatic metabolism. The nurse practitioner understands that the bioavailability of this
medication will be significantly affected by which pharmacokinetic alteration?
A. Decreased absorption from the GI tract
B. Reduced first-pass metabolism leading to increased bioavailability
C. Enhanced renal elimination compensating for hepatic impairment
D. Increased protein binding reducing free drug concentration
, Rationale: In cirrhosis, first-pass hepatic metabolism is reduced due to damaged
hepatocytes and portosystemic shunting, leading to increased bioavailability of drugs that
normally undergo extensive first-pass metabolism. This requires dose reduction to avoid toxicity.
Question 6
A drug has a half-life of 6 hours. Approximately how long will it take to reach steady-state
plasma concentration with a fixed dosing regimen?
A. 6 hours
B. 12 hours
C. 30 hours
D. 60 hours
Rationale: It takes approximately 5 half-lives to reach steady state. 5 × 6 hours = 30 hours.
This fundamental principle governs drug dosing—clinicians cannot judge whether a drug is
working until steady state is achieved. The same rule applies in reverse: it takes about 5 half-
lives to clear a drug after discontinuation.
Question 7
Which pharmacokinetic process is primarily responsible for the FIRST-PASS EFFECT that reduces
the bioavailability of many orally administered drugs?
A. Gastric acid degradation in the stomach
B. Hepatic metabolism via the portal circulation before the drug reaches systemic circulation
C. Renal tubular secretion of the drug
D. Plasma protein binding in the blood
Rationale: The first-pass effect occurs when orally administered drugs are absorbed through
the GI tract into the portal venous system and pass through the liver before reaching systemic
circulation. The liver metabolizes a portion of the drug before it can exert systemic effects,
reducing oral bioavailability.
Question 8
A patient with severe hypoalbuminemia is prescribed phenytoin, a highly protein-bound drug.
What is the most likely clinical consequence of this condition?
, A. Decreased free drug levels, requiring a higher dose
B. Increased free drug levels, increasing the risk of toxicity
C. Increased hepatic clearance of the drug
D. Decreased volume of distribution
Rationale: Albumin is the primary binding protein for phenytoin. Low albumin leaves more
unbound, active drug in circulation. For highly protein-bound drugs, hypoalbuminemia increases
the free (active) fraction, increasing the risk of toxicity even at "normal" total drug levels.
Question 9
A 75-year-old patient is started on a new medication that is primarily metabolized by the liver.
Due to age-related physiological changes, what pharmacokinetic alteration is most likely to
occur?
A. Increased hepatic blood flow and faster metabolism
B. Decreased liver mass and reduced hepatic enzyme activity, leading to slower metabolism
C. Increased renal tubular secretion
D. Decreased gastric pH, enhancing absorption
Rationale: Aging is associated with a reduction in liver size and hepatic blood flow, which
decreases the metabolism of many drugs. Older adults often require lower doses of hepatically
cleared medications. Phase I reactions (CYP450-mediated) are particularly affected by aging.
Question 10
A 70-year-old male with reduced creatinine clearance of 35 mL/min is prescribed gentamicin for
a serious infection. The NP adjusts the dosing interval rather than the dose. This adjustment is
based on which pharmacokinetic principle?
A. Reduced renal clearance increases the volume of distribution
B. Decreased renal elimination prolongs the drug half-life requiring longer intervals
C. Renal impairment increases drug absorption from the GI tract
D. Reduced kidney function enhances hepatic metabolism of aminoglycosides
Rationale: In renal impairment, gentamicin elimination is reduced, prolonging the half-life.
Extending the dosing interval allows more time for drug elimination between doses, preventing
accumulation and toxicity while maintaining peak concentrations for efficacy.
of the Fundamentals Exam | Questions and Verified Answers
(2025/ 2026 Update)- Chamberlain
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Questions 1–30
Question 1
A nurse practitioner is calculating the time required for a drug to reach steady-state plasma
concentration in a patient. Which pharmacokinetic parameter is primarily used to determine
this timeframe?
A. Volume of distribution
B. Bioavailability
C. Elimination half-life
D. Clearance rate
Rationale: The elimination half-life determines the time to reach steady state. It takes
approximately 4–5 half-lives to achieve steady-state plasma concentration. Volume of
distribution affects loading dose calculations, while bioavailability affects the fraction of drug
reaching systemic circulation. Clearance determines the maintenance dose required.
Question 2
A patient is prescribed oral morphine for severe pain but reports it is much less effective than
the intravenous morphine received in the hospital. This difference in efficacy is primarily due to
which pharmacokinetic concept?
A. First-pass effect
B. Enterohepatic recirculation
C. Active tubular secretion
D. Zero-order elimination
Rationale: Oral morphine undergoes extensive hepatic metabolism before reaching
systemic circulation, significantly reducing its bioavailability compared to intravenous
administration. The first-pass effect describes metabolism of an orally administered drug by the
liver via the portal circulation before it reaches systemic circulation, reducing the fraction of
active drug available.
,Question 3
The therapeutic index of a drug is defined as:
A. The ratio of the minimum effective dose to the maximum tolerated dose
B. The ratio of the toxic dose to the effective dose for 50% of the population
C. The difference between peak and trough drug concentrations
D. The ratio of the drug's half-life to its dosing interval
Rationale: The therapeutic index is the ratio of TD₅₀ (toxic dose for 50% of population) to
ED₅₀ (effective dose for 50% of population). A narrow therapeutic index means there is a small
margin between therapeutic and toxic doses, requiring careful monitoring. Drugs with narrow
therapeutic indices include warfarin, digoxin, lithium, and phenytoin.
Question 4
A drug that binds to a receptor and produces a biological response is best described as a:
A. Antagonist
B. Partial agonist
C. Agonist
D. Allosteric modulator
Rationale: An agonist binds to a receptor and activates it, producing a biological response.
Antagonists bind to receptors but do not activate them (they block the receptor). Partial
agonists produce a submaximal response even when all receptors are occupied. Allosteric
modulators bind at a site different from the primary ligand binding site.
Question 5
A 65-year-old male with cirrhosis is prescribed a medication that undergoes extensive first-pass
hepatic metabolism. The nurse practitioner understands that the bioavailability of this
medication will be significantly affected by which pharmacokinetic alteration?
A. Decreased absorption from the GI tract
B. Reduced first-pass metabolism leading to increased bioavailability
C. Enhanced renal elimination compensating for hepatic impairment
D. Increased protein binding reducing free drug concentration
, Rationale: In cirrhosis, first-pass hepatic metabolism is reduced due to damaged
hepatocytes and portosystemic shunting, leading to increased bioavailability of drugs that
normally undergo extensive first-pass metabolism. This requires dose reduction to avoid toxicity.
Question 6
A drug has a half-life of 6 hours. Approximately how long will it take to reach steady-state
plasma concentration with a fixed dosing regimen?
A. 6 hours
B. 12 hours
C. 30 hours
D. 60 hours
Rationale: It takes approximately 5 half-lives to reach steady state. 5 × 6 hours = 30 hours.
This fundamental principle governs drug dosing—clinicians cannot judge whether a drug is
working until steady state is achieved. The same rule applies in reverse: it takes about 5 half-
lives to clear a drug after discontinuation.
Question 7
Which pharmacokinetic process is primarily responsible for the FIRST-PASS EFFECT that reduces
the bioavailability of many orally administered drugs?
A. Gastric acid degradation in the stomach
B. Hepatic metabolism via the portal circulation before the drug reaches systemic circulation
C. Renal tubular secretion of the drug
D. Plasma protein binding in the blood
Rationale: The first-pass effect occurs when orally administered drugs are absorbed through
the GI tract into the portal venous system and pass through the liver before reaching systemic
circulation. The liver metabolizes a portion of the drug before it can exert systemic effects,
reducing oral bioavailability.
Question 8
A patient with severe hypoalbuminemia is prescribed phenytoin, a highly protein-bound drug.
What is the most likely clinical consequence of this condition?
, A. Decreased free drug levels, requiring a higher dose
B. Increased free drug levels, increasing the risk of toxicity
C. Increased hepatic clearance of the drug
D. Decreased volume of distribution
Rationale: Albumin is the primary binding protein for phenytoin. Low albumin leaves more
unbound, active drug in circulation. For highly protein-bound drugs, hypoalbuminemia increases
the free (active) fraction, increasing the risk of toxicity even at "normal" total drug levels.
Question 9
A 75-year-old patient is started on a new medication that is primarily metabolized by the liver.
Due to age-related physiological changes, what pharmacokinetic alteration is most likely to
occur?
A. Increased hepatic blood flow and faster metabolism
B. Decreased liver mass and reduced hepatic enzyme activity, leading to slower metabolism
C. Increased renal tubular secretion
D. Decreased gastric pH, enhancing absorption
Rationale: Aging is associated with a reduction in liver size and hepatic blood flow, which
decreases the metabolism of many drugs. Older adults often require lower doses of hepatically
cleared medications. Phase I reactions (CYP450-mediated) are particularly affected by aging.
Question 10
A 70-year-old male with reduced creatinine clearance of 35 mL/min is prescribed gentamicin for
a serious infection. The NP adjusts the dosing interval rather than the dose. This adjustment is
based on which pharmacokinetic principle?
A. Reduced renal clearance increases the volume of distribution
B. Decreased renal elimination prolongs the drug half-life requiring longer intervals
C. Renal impairment increases drug absorption from the GI tract
D. Reduced kidney function enhances hepatic metabolism of aminoglycosides
Rationale: In renal impairment, gentamicin elimination is reduced, prolonging the half-life.
Extending the dosing interval allows more time for drug elimination between doses, preventing
accumulation and toxicity while maintaining peak concentrations for efficacy.
